Trials / Recruiting
RecruitingNCT05817227
Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is multicentric, spontaneous, observational, retrospective and prospective study.
Detailed description
In the retrospective part of the study, Tissue Microarrays (TMA) will be prepared from surgical samples of breast tissue from a series of patients with TNBC type breast cancer. In the prospective part of the study will be evaluated the expression of some selenoproteins by ELISA in plasma samples obtained from up to 100 healthy subjects and about 300 (\~100 per year) patients with basally metastatic TNBC breast cancer (150) and metastatic (150) before any treatment.
Conditions
Timeline
- Start date
- 2022-05-19
- Primary completion
- 2027-11-19
- Completion
- 2027-11-19
- First posted
- 2023-04-18
- Last updated
- 2025-12-22
Locations
2 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05817227. Inclusion in this directory is not an endorsement.